



# Ultralow Frequency Transmitted Sound Imaging

---

INVESTOR PRESENTATION

February 2024

# Disclaimer

## ABOUT THIS PRESENTATION

This investor presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Proposed Business Combination”) between QT Imaging, Inc. (“QT Imaging™”) and GigCapital5, Inc. (“GigCapital5”) and for no other purpose. The information contained herein does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of QT Imaging or the Proposed Business Combination, and none of GigCapital5, QT Imaging, and William Blair & Co. LLC (“William Blair”), or their respective directors, officers, employees, agents, advisors or affiliates makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation, which has not been verified and is subject to change at any time. Viewers of this Presentation should each make their own evaluation of QT Imaging, the Proposed Business Combination and of the relevance and accuracy of the information and should make such other investigations as they deem necessary. To the fullest extent permitted by law, no responsibility or liability whatsoever is accepted by GigCapital5, QT Imaging, or their respective directors, officers, employees, agents, advisors or affiliates for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions contained herein or otherwise arising in connection herewith.

This Presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of GigCapital5, QT Imaging, or any of their respective affiliates, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale would be unlawful. You should not construe the contents of this Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. Any offer to sell securities will be made either (a) pursuant to a definitive subscription agreement (a “Subscription Agreement”) for GigCapital5 and will be made in reliance on an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), for offers and sales of securities that do not involve a public offering, or (b) with respect to the Proposed Business Combination, by means of a joint proxy statement/prospectus of GigCapital5 (the “GigCapital5 proxy statement/prospectus”) that complies with applicable rules and regulations promulgated under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). GigCapital5, QT Imaging and their respective affiliates reserve the right to withdraw or amend for any reason any offering and to reject any Subscription Agreement for any reason. Any public offering of securities shall be made only by means of a prospectus meeting the requirements of the Securities Act.

On June 6, 2017, the U.S. Food and Drug Administration (“FDA”) in response to QT Imaging’s Section 510(k) Summary of Safety and Effectiveness premarket notification under the Food, Drug and Cosmetic Act, determined that the QT Breast Scanner is substantially equivalent to the predicate device. Our use of the words “safe”, “safety”, “effectiveness”, and “efficacy” in relation to the QT Breast Scanner in this Presentation, in the proxy statement/prospectus and all other QT Imaging related documents is limited to the context of the Section 510(K) Summary of Safety and Effectiveness that was reviewed and responded to by the FDA.

# QT Imaging Has the Potential to Transform Medical Imaging

- QTI is a medical device company with imaging technology that has the **potential to transform the industry**
- QTI Scanner is **the only imaging device to receive FDA clearance** for use as a transmission ultrasonic imaging system of a patient's breast
- QTI's patent-protected technology provides a relatively low-cost, comprehensive, no radiation medical imaging solution **yielding ~40x the resolution of MRI**
- This sub-millimeter, high-definition, image resolution enables the **identification of normal and abnormal breast structures** and the accurate depiction of the precise shape and location of findings, as well as being suitable for **full body imaging and other applications**
- QTI was founded by CEO John Klock, MD, who is recognized globally as a **successful co-founder of multiple companies**, including one that successfully commercialized five FDA-approved drugs

# Introduction to the QT Imaging Management Team

CEO & CHIEF  
MEDICAL  
OFFICER



**John Klock, MD**

Dr. Klock co-founded QT Imaging in 2011 and spearheaded the development and commercialization of the QT Scanner. Prior to QTI, he was involved in the founding of multiple disruptive medical companies, including **BioMarin Pharmaceuticals** (\$20B market cap) where he served as President. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications and holds 8 granted patents.

CHIEF  
FINANCIAL  
OFFICER



**Stas Budagov**

Mr. Budagov is serving as Interim CFO of QTI since December 2023. He has more than 15 years of accounting and consulting experience, including consulting public and private clients. Additionally, he has 3 years of audit experience at Ernst & Young. Mr. Budagov is a graduate of George Mason University with a BS in Accounting.

CHIEF  
PRODUCT  
OFFICER



**Nasser Pirshafiey, MBA**

Mr. Pirshafiey has been with QTI since 2017. Previously, he founded and managed a consulting firm providing sustainable practices to industries including medical device, high-tech, and consumer products for giants such as Johnson & Johnson and Siemens. He has 14 inventions filed with the US patent office.

# Our Mission

- Develop a **safe, more accurate** comprehensive imaging system, while **increasing the speed** and **lowering the cost** of medical imaging
- Develop an **FDA-cleared**, innovative imaging system capable of **detecting masses in dense breasts**
- Develop a safe, full-body imaging technology that can be at the **point of care**
- Improve medical outcomes globally by **increasing access** to medical imaging
- Develop a safe, more accurate comprehensive imaging system for **healthy persons and infants** with preventative screening applications



NIH has awarded QT  
Imaging over  
**\$15.5M**  
for new women's  
imaging solution

# Executive Summary

- **Low-cost, comprehensive, no radiation medical imaging solution** yielding sub-millimeter, high-definition, image resolution: application in areas such as **breast • infant body • orthopedics**
- Commercial stage, FDA-cleared<sup>(1)</sup> breast scanner **for dense breast imaging**, with better sensitivity and specificity than mammography and potential for:
  - Applicability to determine breast density and measure mass size and growth
  - Improved compliance with screening guidelines
  - Expanded FDA clearances to increase access to medical imaging in multiple applications, including preventative screening
- **Breakthrough Device Designation awarded by the FDA** provides fast track to unique CPT codes and future clearances
- Patent-protected technology: **12 granted US/Europe • 1 pending**
  - Software platform protected by trade secrets
- **Sales Agent Agreement signed with NXG Imaging (A Subsidiary of Canon Medical Systems)**
- Go-to-market strategy:
  - **US:** Combination of direct sales force and distributor network
  - **OUS / Global:** Partnerships with strategics & distributors in key regions **Asia • Europe • Middle East • North Africa**
- Developed roadmap for additional FDA clearances, product development, clinical adoption, and commercialization
- Experienced management team supported by successful SPAC management team



# QTI's Technology Has the Opportunity to Transform Several Large Markets

2022 GLOBAL MEDICAL IMAGING MARKET SIZE: \$29B<sup>(1)</sup>

## Current Market

BREAST: \$5B MARKET<sup>(2)</sup>

- FDA approved as supplementary screening device for breast imaging
- Goal to replace all or part of current imaging paradigm which includes mammography, ultrasound (handheld and automated), and MRI



## Future Markets – Body Scanner Platform Development

ORTHO: \$9B MARKET<sup>(3)</sup>

- Target replacing MRI examinations
- Primary focus on orthopedic practices




INFANT: \$8B MARKET<sup>(4)</sup>

- New market opportunity given limitations of current imaging modalities for infants



IMAGE-GUIDED PROCEDURES: \$5B MARKET<sup>(5)</sup>

- Commenced feasibility study
- Variety of image-guided procedures including biopsies, injections and cryoablation



(1) Medical Imaging Market Size, Share & Trends Analysis Report by Products (X-Ray, Ultrasound, Computed Tomography, Magnetic Resonance Imaging (MRI), Nuclear Imaging), by End Users (Hospitals, Diagnostic Imaging Centers, Other End Users), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028), Vantage Market Research

(2) Coherent Market Insights

(3) Global Orthopedic Medical Imaging Systems Market Analysis Report 2022: Market to Reach \$10.6 Billion by 2026 - The US Corners Orthopedic Medical Imaging Market with Adoption of Innovative Systems, Research and Markets.

(4) Pediatric Imaging Market Size, Share & Trends Analysis Report By Modality (X-ray, Ultrasound; MRI, CT), By Application (Gastroenterology, Cardiology, Oncology), By End User, By Region, And Segment Forecasts, 2020 - 2027, Grandview Research.

(5) Image-guided Therapy Systems Market Size, Share & Trends Analysis Report By Product (Ultrasound Systems, Computed Tomography Scanners), By Application, By End-use, And Segment Forecasts, 2022 - 2030, Grandview Research.


# Investment Highlights

*Cutting-edge imaging technology with multiple potential applications creates a tremendous opportunity to transform the imaging market*

Industry-Transforming Imaging Technology Platform Recognized by Industry Incumbents




Differentiated Solution in Large and Important, \$5B<sup>(1)</sup> Breast Screening Market



Potential to Significantly Expand TAM Through Adjacent Market Applications



QT imaging



NXC Imaging Agreement to Drive Accelerated Commercial Roll-out

Recent Changes to FDA Rules and USPSTF Guidance on Breast Screening Provide Meaningful Tailwinds and Momentum



Experienced and Committed Executive Suite



(1) Coherent Market Insights

# Agreement Signed with NXC Imaging (A Subsidiary of Canon Medical Systems)

- Sales Agent Agreement signed with NXC Imaging marks a major milestone for QT Imaging
- Accessing NXC Imaging's distribution channel in the US and the US territories, this agreement provides potential to accelerate the commercial roll-out of QT's imaging system
- NXC Imaging will also provide a mature service organization to support the QT Imaging's installed base



# TECHNOLOGY OVERVIEW

# Current Ultrasound Technologies Have Major Deficiencies

## Shortfalls of Current, Rival Systems

- Reflection and compounding artifacts
- No valid true “transmission” mode – use “shear wave” (low resolution) data
- Data yielded is compounded 2D – not true “3D”
- “Speed” photos provide compromised resolution
- Low contrast-to-noise ratios
- Specificity for masses is poor
- Unable to view calcifications – misses 20% of cancers<sup>(1)</sup>
- No “functional” imaging features (doubling time, tissue identification and specific tissue volume segmentations)
- Poor reproducibility of measurement and volume data



## Critical Modality Advantages of QT<sup>(2)</sup>


- Clinically useful sensitivity and specificity
- Presence of comparative clinical trials
- Proven success in head-to-head trials against mammography for primary screening
- Ability for doubling times – can identify slow growing cancers and help prevent cancer deaths
- Enhanced volume measurements – can follow cancer treatments and provide breast density measurements
- Patented technology opens the door for potential future growth in orthopedic and pediatric imaging

(1) Based on opinion of QT Imaging. See Form S4/A for further details/explanation

(2) Based on opinion of QT Imaging. QT<sup>i</sup> believes necessary data has been obtained through 18 separate clinical trials

# Why Does QTI Volography Have 40x the Resolution of The Best MRI? More Data

planar MRI




22 million voxels

Data points per voxel = 183,184  
~180 thousand data points

QTI Volography (3D)

volumetric  
QTI



QT duplication of data means:

- Higher Resolution
- Higher Detection
- Higher Signal to Noise

Data points per voxel = 36,238,786,560  
~36 billion data points

~ 200,000 times more data per voxel than ( $N_{MRI}$ )

# Transmission Ultrasound Capabilities

## Technical


- Resolution of 50-100 microns compared to ....for MRI
- Contrast to noise ratio of 23:1 at 100 microns
- Artifact-free because of speed correction of reflection vologram
- Volumetric data acquisition, not stacked 2D slices
- Volumetric accuracy of  $\pm 0.2\%$

## Clinical

- Clinical detection of 50-100 microns including microcalcifications
- Functional imaging capability - determine tissue type from the speed of sound
- Functional imaging capability - allows tissue doubling time assessments
- Highly accurate measurements, not operator dependent


# Resolution and Detectability: MRI vs QTI Volography (3D UT)

## MRI



*MRI image of a piglet lung*


## QTI Volography



~40x

resolution of 3T MRI

*MRI resolution depends on acquisition time, B1 inhomogeneity, etc.*



Volography (3D UT) with reflection mode

- Resolution is almost isotropic
- Sub-mm resolution
- Detectability 0.05 mm


*First time structures as small as the lung alveoli can be seen in vivo!*



# BREAST HEALTH

# QT Imaging's FDA-cleared Solution for Dense Breasts


MANY WOMEN HAVE DENSE BREASTS, WHICH MAMMOGRAMS ARE INEFFICIENT IN SCREENING FOR CANCER



■ Dense Breast ■ Other

50% of women between the ages of 40-74 in the US have dense breasts<sup>(1)</sup>

In **~84%** of cases observed in a recent mini-study, QT Scanner identified abnormalities in dense breasts that were **not identified by x-ray mammograms**<sup>(2)</sup>



X-Ray Mammogram QT Scan

THE FDA HAS RECOGNIZED THE IMPORTANCE OF BREAST DENSITY IN BREAST CANCER SCREENING

## Mammograms Must Include Breast Density Information, New FDA Rule Says<sup>(3)</sup>

About half of the women over the age of 40 in the U.S. have dense breast tissue, which can make cancer scans hard to read



*“the new rule advises physicians and patients to consider breast density alongside other cancer risk factors when deciding whether additional screening is necessary”*

– Hilary Marston, Chief Medical Officer FDA

*Mammography Misses 35.6–52.2% Of Breast Cancers In Dense Breast Tissue<sup>(4)</sup>*

(1) Breast Density on a Mammogram, Susan G. Komen


(2) QTI Study | Dense Breast Mass Detection

(3) “Mammograms Must Include Breast Density Information, New FDA Rule Says”. Wall Street Journal


(4) The Role of Ultrasound in Screening Dense Breasts. NCBI.

# CLINICAL TRIALS: Dense Breast Imaging Study Confirmed DBT = 40% False-Negatives


Approximately 50% of women between the ages of 40-74 in the US have dense breasts<sup>(1)</sup>, with traditional mammography missing 35.6-52.2% of breast cancers in dense breast tissue<sup>(2)</sup> making QT Scanner the only system effective at screening dense breast




IMPLANT WITH MASS



CALCIFICATION



CANCER



CYSTS

*QTI can see calcification missed by other imaging systems and is particularly effective in imaging dense breasts*

(1) Breast Density on a Mammogram, Susan G. Komen  
(2) The Role of Ultrasound in Screening Dense Breasts. NCBI.

# Other Ultrasound Products Use B-mode Imaging for Dense Breast Screening



INVENIA ABUS



SIEMENS

ACUSON S2000 ABVS



SonoCiné

AWBUS



HITACHI

SOFIA 3D



Delphinus  
Medical Technologies

DELPHINUS SOFTVUE



QT imaging™

QT BREAST SCANNER



## DESIGN TYPE

Articulating Arm

Articulating Arm

Articulating Arm  
Guided Handheld


Rotating Armature

Water Bath


Water Bath

## OUTPUT


Stacked 2D  
Reflection Slices




Stacked 2D  
Reflection Slices




Stacked 2D  
Reflection Slices




Stacked 2D  
Reflection Slices



Stacked 2D  
Slices



Only  
Full 3D



*Mammography is ineffective in screening dense breasts. Ultrasound techniques performed after MRI did not detect additional cancer<sup>(1)</sup> in dense breast*

Source: Manufacturer's websites


(1) Integration of Handheld Ultrasound or Automated Breast Ultrasound among Women with Negative Mammographic Screening Findings: A Multi-center Population-based Study in China

Copyright © 2023 QT Imaging, Inc. All Rights Reserved.



# The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs


## SCREENING COMPLIANCE IS LOW



OF THE 65% OF WOMEN WHO DO GET SCREENED, MANY SUFFER THROUGH UNNECESSARY CALLBACKS. Aside from the discomfort of the mammogram procedure, **up to 15% of women are called back** for additional procedures such as ultrasound, MRI or biopsies – which can be **expensive, time consuming and cause significant anxiety**<sup>(2)</sup>

## FOR EVERY 1,000 SCREENING MAMMOGRAMS:

**FALSE-NEGATIVE RATES**  
~15% false-negative rates with mammography



98% OF  
RECALLS ARE  
AVOIDABLE

**BIOPSIES**  
~10% biopsy rate for callbacks



OVER 80% OF  
CALLBACK  
BIOPSIES ARE  
BENIGN<sup>(4)</sup>

**CANCER INCIDENCE**  
0.3% cancer diagnosis<sup>(5)</sup>



(1) Mammography. Center for Disease Control and Prevention

(2) Very Well Health | 13 Reasons for a Mammogram Callback | Larell Scardelli

(3) PubMed | False-Negative Rate of Combined Mammography and Ultrasound for Women with Palpable Breast Masses | Carlos H.F. Chan, Suzanne B. Coopey, Phoebe E. Freer, and Kevin S. Hughes

(4) National Breast Cancer Foundation | Breast Biopsy: Procedure Types, What to Expect and Results

(5) U.S. Breast Cancer Statistics. Breastcancer.org.

# Current and Future Uses of QT Breast Scanner

*The QT Breast Scanner has been granted FDA clearances that allow for meaningful clinical use, with potential for a future roadmap to provide a replacement to screening mammography, a transformational milestone that would significantly expand the market opportunity*

## CURRENT APPLICATION

- **Currently used in clinics for both primary and supplementary screening, upon MD or self-referral can be used for screening but cannot be marketed as a replacement for the mammogram at this time**
- **FDA clearances in place:**
  - Breast Imaging (K162372)
  - Software Improvements (K181785, K190626)
  - Breakthrough Device Designation (Q181785)
  - Measure Fibroglandular Volume (K220993)

- “The QT Ultrasound Breast Scanner – 1 is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.”

– *Food and Drug Administration*

*510(k) Premarket Notification of Intent K162372*

- “The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection mode and transmission-mode images of a patient’s breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value as determined from reflection-mode and transmission mode ultrasound images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.

The QT Scanner 2000 Model A is indicated for use by trained healthcare professionals in environments where healthcare is provided to enable breast imaging in adult patients.”

– *Food and Drug Administration*

## FUTURE POTENTIAL APPLICATIONS

**Near-term:** (18 months)

- Use applicability for **determining breast density, measuring mass size and growth, and diagnosing lesions using artificial intelligence** to expand into supplementary imaging market
- FDA has granted QT Scanner a **Breakthrough Device Designation**

**Medium-term:**

- **Screening for High-Risk (Family History and Genes) Young Women:** providing at-risk young women a safe, comfortable, and accurate method to screen for breast cancer

**Long-term (major milestone):**

- **Alternative to Screening Mammography:** our goal is to provide all women a safe, comfortable, and accurate method to screen for breast cancer

# QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring

## SUPPLEMENTAL SCREENING

- **Complementary screening (Approved)**
  - Dense Breasts
  - Intermediate to high-risk women
  - Implants
- Primary screening for mammogram underserved patients (age <35)
  - Young, high-risk women with predisposal to cancer or previous chest radiation
  - Any woman who believes they are at risk
- Adjunctive and/or alternative to handheld ultrasound
- Alternative to breast MRI with gadolinium injection



## DIAGNOSIS

- **Quantification of fibroglandular volume (Approved)**
- AI-enabled diagnostics
- Accurate tumor size
- Potential for biopsy procedures with the 2<sup>nd</sup> generation open angle scanner (currently under development)
- Imaging techniques can detect accurately growth rate of tumors, thus identifying aggressive cancers



## MONITORING

- Ability to safely use repeatedly – no side effects/non-invasive
- Measure and track mass size and growth
- Assess response to treatments

*QTI imaging technique has the capability to replace MRI for dense breasts (no injection, no discomfort)*

# The QT Scanner Delivers a Better Experience for Patients than Traditional Systems


Image Quality

Safety<sup>(1)</sup>


Speed

Cost Efficiency

Patient Experience



QT IMAGING




HANDHELD ULTRASOUND



...OVER HHUS

- Superior image quality
- Not operator dependent
- Quantifiable/repeatable




MRI



...OVER MRI

- High resolution and contrast-to-noise ratio
- Faster, with no injection needed
- Lower equipment cost
- No special facility or shielding requirements



MAMMOGRAPHY



...OVER MAMMOGRAPHY

- Improved image quality
- Safer (no radiation), allowing for more frequent imaging
- Greater sensitivity and specificity
- No special facility requirements
- Quantifiable/repeatable



The QTI  
Imaging  
Advantage

(1) No radiation exposure or injections necessary

# QTI's Breast Acoustic CT™ Technology

## Technical Performance

- Very high clinical perspicuity
- 10x sensitivity of 3T MRI
- >5x contrast to noise ratio (CNR) of 3T MRI

## Isotropic Image

- Very few artifacts
- Very accurate linear and volume measurements - + 0.2%
- Can see calcifications and other low signal structures not seen in mammography, HHUS and MRI
- Can see small anatomical structures (glands vs ducts, ductal calcifications, cyst vs solid masses)

## QT Scan™

- Has higher sensitivity for lesions and higher specificity and fewer call-backs than screening mammography
- Over 10% improved AUC-ROC in two large clinical trials
- Over 16% fewer callbacks
- Fewer false positives

# QTI Clinical Trials Provide Compelling Results for Adoption and Approvals

## Clinical Trials

- Visual Grading Assessment of Quantitative Transmission Ultrasound Compared to Digital X-ray Mammography and Hand-held Ultrasound
- Anatomy-Correlated Breast Imaging and Visual Grading Analysis Using Quantitative Transmission Ultrasound
- Accuracy of Cyst vs. Solid Diagnosis in the Breast Using Quantitative Transmission (QT) Ultrasound
- Breast Cyst Fluid Analysis Correlations Using Transmission Ultrasound
- Objective Breast Tissue Image Classification Using Quantitative Transmission Ultrasound Tomography
- Quantitative Assessment of Breast Density: Transmission Ultrasound is Comparable to Mammography with Tomosynthesis
- An Exploratory Study Comparing Transmission Ultrasound to Mammography on Recall Rates and Detection Rates for Breast Cancer
- QT Ultrasound Tomography for Orthopedic Imaging
- QT Ultrasound for Whole Body Imaging

## Implication of Results or Preliminary Results

QT can **see more anatomy** than mammography or handheld ultrasound

QT can **distinguish specific tissues** unlike mammography or handheld ultrasound

QT can **quantify breast density** unlike mammography or handheld ultrasound

QT can **identify breast and reduce recall rates** better than mammography

QT can **identify bone and joint structures** better than MRI


QT can **identify internal body structures** better than MRI

Current Support and Partners



# CLINICAL TRIALS: Two Blinded Randomized Trials Completed and Published


## QT PERFORMANCE RELATIVE TO FFDM AND DBT IN MASS DETECTION



VS



## STUDY #2 (Comparison to Digital Breast Tomosynthesis)



*In recent studies, QT outperformed today's gold standard (Digital Breast Tomosynthesis)*

(1) Study #1: An Exploratory Multi-reader, Multi-case Study Comparing Transmission Ultrasound to Mammography on Recall Rates and Detection Rates for Breast Cancer Lesions

(2) Accepted for Publication



# CLINICAL ADOPTION

# Key Milestones Have Been Achieved, with Additional Catalysts to Drive Commercial Adoption and Increased Market Share

KEY MILESTONES

MAJOR MILESTONE

## BREAST SCANNER

18 MONTHS

### Key Milestones Achieved for Commercial Adoption

- ✓ Four placements in North America
- ✓ Three placements internationally
  - Generate and publish clinical data
  - Develop market advocates
- ✓ Signed Sales Agent Agreement with NXC Imaging (A Subsidiary of Canon Medical Systems) for worldwide sales and service rollout



### Catalysts for Further Commercial Adoption

- Screening adjunct clearance for high-risk young women
- Primary screening clearance for all women subject to FDA approval
- Product enhancements while further developing sales and marketing team

FDA Clearance for Primary Screening

*Millions of young, at-risk women can benefit from QTI's potential FDA clearance for primary screening*

# Pricing Structures Allow Providers Flexibility in Using the QT Scanner

## INITIAL TARGET MARKETS



Academic  
Medical  
Centers



Community  
Cancer  
Centers



Private  
Practices



Independent  
Breast Imaging  
Centers

## PRICING MODEL\*

1. Traditional Upfront Purchase
2. MSaaS (Medical Scan as a Service)/Per Click Model
3. Turnkey Model (includes scan interpretation)

\* all require annual maintenance and custom disposables

# Reimbursement Will Be Driven by the Value and Savings Provided to Patients

## CURRENT

- Existing CPT codes, non-specific to QTI technology:
  - Unilateral or Bilateral breast ultrasound (76641 or 76642)
  - 3D rendering (76377)
  - Other ultrasound procedures (76999)

## FUTURE

- CPT code specific to QT Scanner®
  - Higher reimbursements capture full value of unique advantages that QT Scans offer
  - Process to QTI-specific code facilitated by breakthrough designation
- Reimbursement agreements with specific insurance companies and programs
  - Integrated health systems focused on minimizing overall cost of care
  - Programs serving higher risk groups






# OPEN ANGLE SCANNER

# Developing an Open Angle Scanner Will Expand the Technology to New Markets

## DEVELOPMENT OF THE OPEN ANGLE SCANNER IS UNDERWAY...

- QTI has successfully completed feasibility studies for partial angle reconstruction
- QTI has verified the ability to perform data acquisition and image reconstruction with a membrane within the field
- Working to design a platform that accommodates orthopedic and infant imaging



*The Open Angle Scanner has the potential to offer a safe and affordable in-office imaging solution*

## ... PROVIDING SIGNIFICANT POTENTIAL TO ACCESS NEW MARKETS AND APPLICATIONS

- The Open Angle Scanner uses an open, partial angle configuration which reduces the viewing field from 360° to 325° and provides additional capabilities for QTI technology in:
  - Orthopedic imaging
  - Whole body infant scanning
  - Biopsy and image-guided diagnostic and treatment procedures
- The scanner satisfies the need for better image reconstruction techniques in partial-ring tomography systems
- Potential to prevent cancers from developing into advanced stages
- Representative point-of-care target markets include:



ORTHOPEDIC SURGEONS  
[IN-OFFICE]



SPORTS TEAMS  
[ON THE FIELD]



MILITARY  
[SHIPS & FIELD USE]


# The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner

## NEXT GENERATION OPEN ANGLE SCANNER

18 MONTHS

### Key Infrastructure in Place for Development

- ✓ Underlying ultra-low frequency sound emitting technology
- ✓ Initial Proof of Concept
- ✓ Commencement of prototype design and build



### Upcoming Catalysts for Rollout

- Software development
- FDA approvals
- Similar Sales Agent Agreement such as with CMS for worldwide sales and service rollout


Prototype Design and Build

*Next generation open angle scanner will allow QTI to access adjacent areas such as ortho, infant, and image guided procedures*

KEY MILESTONES

MAJOR MILESTONE

# Open Angle Scanner Development Pathway and Corresponding Catalysts





THANK YOU!